Avellino Labs announced earlier this month it had launched a study to examine the prevalence of corneal dystrophies associated with mutations in the TGFBI gene in North America.
The multicenter study will reportedly include 25 investigational sites in the U.S. and Canada, with 20,000 subjects representative of individuals likely to undergo refractive surgery in North America to be enrolled. Through a buccal swab sample taken from each subject, the study will reportedly determine if each enrolled person demonstrates a mutation associated with one of the five TGFBI dystrophies. Enrollment for the study has already begun and Avellino Labs expects preliminary results could be available as early as the first quarter of 2017.
Click here to read the full press release.